Journal of intensive care medicine
-
J Intensive Care Med · Jan 2009
Randomized Controlled TrialA new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.
To study the effect of immunomodulatory therapy with ulinastatin plus thymosin alpha( 1) on septic patients. ⋯ Combined immunomodulatory therapy with ulinastatin plus thymosin alpha(1) appears to yield improved survival for patients with sepsis; this finding should be verified in larger clinical trials.